Neurofibromatosis is a progressive and autosomal dominant inherited disorder of the nervous system which causes tumors to form on the nerves anywhere in the body, at any time. Neurofibromatosis skin lesions are typically flat, pigmented patches but occasionally are elevated flesh-colored bumps. There are three types of Neurofibromatosis: Type 1 Neurofibromatosis (NF1), Type 2 Neurofibromatosis (NF2) and Schwannomatosis (SWN).
Currently, the Neurofibromatosis sphere constitutes a robust pipeline with more than 17 drugs under different phases of development.
DelveInsight offers a new addition to its newsletter edition that pivots on the Neurofibromatosis market. The newsletter provides a complete picture of the Neurofibromatosis market landscape, ongoing clinical trials, Neurofibromatosis pipeline therapies that are expected to transform the Neurofibromatosis market in the coming decade. Dive deep into rich insights of Neurofibromatosis epidemiological insights, current treatment therapies, details of the latest news and happenings, mergers and collaborations, major pharmaceuticals involved, licensing deals along with events, and top-level conferences.
Keen about what is in store for the Neurofibromatosis market and how pharma companies are working to push the drug development? Download our Newsletter by simply filling up the form towards the right.
Subscribe to our mailing list and stay informed about all the recent breakthroughs in the Genetic Disorders market.
Do check out our recent blog/newsletter/whitepaper on the Neurofibromatosis treatment landscape.
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- R&D in the field
- Top conferences
- News flash
- Recent Research Activities
- Support from International organizations
- Market insights
- Neurofibromatosis Market Dynamics
- Collaborations and deals in the domain